This is a case report of a woman in her 50s who was recently diagnosed with acute myeloid leukaemia and was started on decitabine 20 mg/m 2 (40 mg). She complained of fever, multiple hyperpigmented ...

(Cedazuridine + decitabine) is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for ...

14, 2025 /PRNewswire/ -- Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced today that oral decitabine and ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

An exploratory phase II trial of low-dose decitabine and sintilimab combined with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma. First-line (1L) nivolumab (NIVO) ...

05). All 32 patients first received frontline therapy with azacitidine (61.5%), decitabine (14.4%), oral decitabine (1.5%), HMA with venetoclax (11.1%), or other HMA combinations (11.5%).

If it comes to fruition, etavopivat will give Novo Nordisk a late-stage SCD programme to complement EPI01, an oral, fixed dose formulation of decitabine and tetrahydrouridine that is heading ...

Figure 3. Mechanism illustration of demethylation drugs in endometrial cancer. Nucleoside analog decitabine and non-nucleoside inhibitor RG108 reduce MLH1 methylation levels by inhibiting DNMT3B, ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today ...